Tempest Therapeutics, Inc. develops clinical-stage cell therapy and small-molecule product candidates for cancer and related disease areas. News about TPST centers on its dual-targeting CAR-T platform, including TPST-2003, a CD19/BCMA CAR-T therapy under development for relapsed or refractory multiple myeloma, and clinical updates from programs such as REDEEM-1 and POEMS-1.
Company updates also cover CAR-T manufacturing and technology-transfer work, partner-supported development activities, business development and licensing priorities, and the amezalpat small-molecule program. Recurring corporate news includes financial results, pipeline portfolio changes following acquired CAR-T assets, leadership appointments, and governance or capital-structure matters tied to the company’s Nasdaq-listed common stock.
Tempest (NASDAQ: TPST) presented updated clinical data for dual-targeting CAR-T candidate TPST-2003 at ISCT on May 6, 2026. Key findings: a 100% complete response rate among 15 CAR-T‑naïve efficacy-evaluable patients across REDEEM-1 and POEMS-1, 44 patients treated to date, no dose-limiting toxicities, and no Grade >3 CRS or ICANS reported.
Data include 10/10 IMWG CR in REDEEM-1 rrMM patients, 5/5 CRVEGF in POEMS-1, and a reported median progression-free survival of 23.1 months noted as potentially class-leading if replicated in registrational trials.
Tempest (Nasdaq: TPST) will present clinical updates for its dual-targeting CAR-T candidate TPST-2003 at ISCT 2026 in Dublin, May 6-9. Data include REDEEM-1 Phase 1/2a interim results showing a 100% complete response rate among six then-evaluable patients per IMWG criteria and a reported favorable safety profile. Presentations include an oral talk (May 6) and poster reception (May 7).
Tempest (Nasdaq: TPST) delivered the TPST-2003 lentiviral vector to Cincinnati Children’s AGCTC, enabling manufacturing activities needed for pivotal development of the dual-targeting CD19/BCMA CAR-T for relapsed/refractory multiple myeloma.
Tempest reported a 100% overall response rate (25/25) across evaluable patients and 100% complete responses in six REDEEM-1 efficacy-evaluable patients; median PFS was 23.1 months in the investigator-initiated trial. Tech transfer is on track to support initiation of a potentially registrational study in Q4 2026.
Tempest (Nasdaq: TPST) appointed Andrew Fang, Ph.D., as Head of Business Development on April 14, 2026, to lead global partnerships, cross-border licensing and China outreach. The hire targets partnering for the Phase 3-ready small molecule amezalpat program and strategic collaborations across Tempest’s CAR-T portfolio.
The company noted prior regulatory alignment with FDA and EMA and clearance to pursue a pivotal trial of amezalpat in China, positioning the program for potential global development and regional licensing opportunities.
Tempest (Nasdaq: TPST) reported year-end 2025 results and a corporate update on March 30, 2026. Key developments include the strategic all-stock acquisition of dual-targeting CAR-T assets from Factor Bioscience, positive interim REDEEM-1 data for TPST-2003 (100% CR in six evaluable patients), regulatory designations for amezalpat, and multiple equity financings.
Financially, cash fell to $7.7M at year-end 2025 from $30.3M, net loss was $26.3M, R&D spend was $12.6M, and Tempest noted partner-funded development strategies moving forward.
Tempest Therapeutics (Nasdaq: TPST) announced a private placement expected to close on or about March 23, 2026 to raise up to $6 million in aggregate proceeds: approximately $2 million upfront and up to $4 million if warrants are fully exercised.
The offering covers 925,927 shares (or pre-funded warrants) and accompanying series A and short-term series B warrants priced at $2.16 per share; warrants require stockholder approval and have defined expiry periods. Proceeds are for working capital and general corporate purposes.
Tempest (Nasdaq: TPST) selected Cincinnati Children’s Applied Gene and Cell Therapy Center (AGCTC) to conduct technology transfer, development and IND‑enabling manufacturing for TPST-2003, a dual‑targeting CD19/BCMA CAR‑T for relapsed/refractory multiple myeloma.
As of a January 31, 2026 cutoff, 36 patients received TPST-2003; all six efficacy‑evaluable REDEEM-1 patients achieved complete response and overall response rate was 100% (25/25) among evaluable patients. Most activities are planned complete by Q3 2026 to support a potential IND filing in Q4 2026.
Tempest (NASDAQ: TPST) reported interim REDEEM-1 results for TPST-2003, a CD19/BCMA dual-targeting CAR-T. Across two studies 36 patients treated; among 25 evaluable with measurable disease ORR was 100% (25/25), and all six REDEEM-1 efficacy-evaluable patients achieved CR. Safety showed no Grade >=3 CRS or ICANS. Tempest plans a U.S. IND submission and, subject to clearance, to initiate a U.S. registrational study in 2026.
Tempest Therapeutics (Nasdaq: TPST) outlined a capital-efficient plan to advance newly acquired dual-targeting CAR-T assets, prioritizing partner-funded development to preserve internal capital. Key priorities include advancing TPST-2003 with near-term Phase 1 data from China, a registrational Phase 2b planned by end-2026, and interim data expected in 2027.
The pipeline expansion includes TPST-4003, an in vivo CD19/BCMA CAR-T program aimed at preclinical development and partner-funded investigator trials, plus continued development of amezalpat (Phase 3-ready HCC) and a NCI-funded Phase 2 for TPST-1495 with enrollment expected in Q1 2026.
Tempest (Nasdaq: TPST) closed an all-stock acquisition of dual-targeting CAR-T programs and secured strategic partner funding from Factor Bioscience, adding clinical-stage assets including TPST-2003. The deal extends operational runway to mid-2027, supports multiple near-term milestones, and installs Matt Angel, Ph.D., as President and CEO.
Key program highlights: TPST-2003 has completed a Phase 1 rrMM study with China BLA planned for 2027; TPST-2003 is enrolling POEMS patients with data and a China BLA planned by 2028; TPST-1120 remains Phase 3 ready in first-line HCC.